Takahiko Shimizu

Although insulin resistance increases the risk of Alzheimer's disease (AD), the mechanisms remain unclear, partly because no animal model exhibits the insulin‐resistant phenotype without persistent hyperglycemia. Here we established an AD model with whole‐body insulin resistance without persistent hyperglycemia (APP/IR‐dKI mice) by crossbreeding constitutive knock‐in mice with P1195L‐mutated insulin receptor (IR‐KI mice) and those with mutated amyloid precursor protein ( App NL‐G‐F mice: APP‐KI mice). APP/IR‐dKI mice exhibited cognitive impairment at an earlier age than APP‐KI mice. Since cholinergic dysfunction is a major characteristic of AD, pharmacological interventions on the cholinergic system were performed to investigate the mechanism. Antagonism to a nicotinic acetylcholine receptor α7 (nAChRα7) suppressed cognitive function and cortical blood flow (CBF) response to cholinergic‐regulated peripheral stimulation in APP‐KI mice but not APP/IR‐dKI mice. Cortical expression of Chrna7 , encoding nAChRα7, was downregulated in APP/IR‐dKI mice compared with APP‐KI. Amyloid β burden did not differ between APP‐KI and APP/IR‐dKI mice. Therefore, insulin resistance, not persistent hyperglycemia, induces the earlier onset of cognitive dysfunction and CBF deregulation mediated by nAChRα7 downregulation. Our mouse model will help clarify the association between type 2 diabetes mellitus and AD.